Post-marketing surveillance on Guizhi Fuling Jiaonang based on literature review.
10.19540/j.cnki.cjcmm.20180126.002
- Author:
Gui-Qian WANG
1
;
Yang GAO
1
;
Fu-Mei LIU
1
;
Rui-Li WEI
1
;
Yan-Ming XIE
1
Author Information
1. Institute of Basic Research in Clinical Medicine， China Academy of Chinese Medical Sciences， Beijing 100700， China.
- Publication Type:Journal Article
- Keywords:
Guizhi Fuling Jiaonang;
adverse reaction;
literature review;
safety
- MeSH:
Drug-Related Side Effects and Adverse Reactions;
Drugs, Chinese Herbal;
adverse effects;
Humans;
Product Surveillance, Postmarketing;
Randomized Controlled Trials as Topic;
Wolfiporia;
chemistry
- From:
China Journal of Chinese Materia Medica
2018;43(4):820-832
- CountryChina
- Language:Chinese
-
Abstract:
To systemically evaluate the post-marketing safety of Guizhi Fuling Jiaonang. Computer retrieval was conducted in Medline, EMbase, the Web of Science, Clinical Trials. Gov, the Cochrane Library, CNKI, VIP, WanFang Data and CBM to collect relevant information. The papers were then screened according to inclusion and exclusion criteria. A total of 234 papers were included in this study, including 164 randomized controlled trials, 7 quasi-randomized controlled trials, 8 non-randomized controls, 56 case series, and 1 cohort study. The patients were only treated with Guizhi Fuling Jiaonang in 56 studies, and Guizhi Fuling Jiaonang was combined with other drugs in 178 studies. The total ADRs/AEs incidence was 1.99% in single use of Guizhi Fuling Jiaonang, and 8.21% in combined use, but showing no severe adverse reactions. Gastrointestinal system damage was most common in mild ADRs. In this study, it was found that the overall safety of Guizhi Fuling Jiaonang was acceptable. The direct evidences of the drug's safety case reports were systematically analyzed in this study, but the mechanism study on the safety of the drug after marketing or the prospective long-term clinical observation study was not sufficient, so the further studies on the safety of drug use should be conducted in order to provide better guidance for clinical medication.
